STOCK TITAN

Black Diamond Therapeutics, Inc. - $BDTX STOCK NEWS

Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: $BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Black Diamond Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Black Diamond Therapeutics's position in the market.

Rhea-AI Summary
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced that its President and CEO, Mark A. Velleca, M.D., Ph.D., will participate in fireside chats at two investor conferences in November 2023. Webcasts will be available on the company's website, with replays accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
conferences
-
Rhea-AI Summary
Black Diamond Therapeutics reports positive Phase 1 data for BDTX-1535 in NSCLC patients and provides corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary
Black Diamond Therapeutics to present at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, showcasing Phase 1 data for BDTX-1535 in NSCLC and GBM, and preclinical data for BDTX-4933.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
conferences clinical trial
Rhea-AI Summary
Mark Velleca appointed CEO of Black Diamond Therapeutics, replacing David Epstein. Velleca aims to advance the company's clinical stage programs and create value for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary
Black Diamond Therapeutics announces dosing of first patients in mutation matched expansion cohorts of NSCLC clinical study for BDTX-1535
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
-
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) to participate in three upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences
Rhea-AI Summary
Black Diamond Therapeutics reports positive initial clinical data for BDTX-1535 in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations. Expansion cohorts initiated. Underwritten public offering raises $75.0 million. Cash position of $89.5 million. Milestones include FDA meeting and clinical update in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.22%
Tags
Black Diamond Therapeutics, Inc.

Nasdaq:BDTX

BDTX Rankings

BDTX Stock Data

306.02M
35.92M
2.61%
93.57%
3.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About BDTX

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.